Formulation and in vivo evaluation of effervescent inhalable carrier particles for pulmonary delivery of nanoparticles

Drug Development and Industrial Pharmacy

Volumn 34, Issue 9, 2008, Pages 943-947

  Azarmi, Shirzad ^a,b   Löbenberg, Raimar ^a   Roa, Wilson H ^a   Tai, Shusheng ^a   Finlay, W H ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Carrier particles; Cyanoacrylate; Effervescent; Nanoparticle; Pulmonary delivery

Indexed keywords

DRUG CARRIER; ENBUCRILATE; NANOPARTICLE;

AEROSOL; ANIMAL EXPERIMENT; ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; EFFERVESCENT POWDER; FEMALE; FREEZE DRYING; LIGHT SCATTERING; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; POWDER INHALER;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; FEMALE; LUNG; MICE; MICE, INBRED BALB C; NANOPARTICLES; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE;

EID: 52149095437     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040802149079     Document Type: Article

References (12)

1. Azarmi, S., Roa, W. H., & Lobenberg, R. (2008). Targeted delivery of nanoparticles for the treatment of lung diseases. Adv. Drug Deliv. Rev., 60(8), 863-875.
2. Azarmi, S., Tao, X., Chen, H., Wang, Z., Finlay, W. H., Löbenberg, R., & Roa, W. H. (2006). Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int. J. Pharm., 319, 155-161.
3. Brzoska, M., Langer, K., Coester, C., Loitsch, S., Wagner, T. O. F., & Mallinckrodt, C. V. (2004). Incorporation of biodegradable nanoparticles into human airway epithelium cells - in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases. Biochem. Biophys. Res. Commun., 318(2), 562-570.
4. Dailey, L. A., Jekel, N., Fink, L., Gessler, T., Schmehl, T., Wittmar, M., Kissel, T., & Seeger, W. (2006). Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol. Appl. Pharmacol., 215, 100-108.
5. Ely, L., Roa, W., Finlay, W. H., & Löbenberg, R. (2007). Effervescent dry powder for respiratory drug delivery. Eur. J. Pharm. Biopharm., 65(3), 346-353.
6. Finlay, W. H. (2001). The mechanics of inhaled pharmaceutical aerosols: An introduction. San Diego, CA: Academic Press.
7. Labiris, N. R., & Dolovich, M. B. (2003). Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol., 56, 588-599.
8. Oberdorster, G., Oberdorster, E., & Oberdorster, J. (2005). Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect., 113, 823-839.
9. Sham, J. O. H., Zhang, Y., Finlay, W. H., Roa, W. H., & Loebenberg, R. (2004). Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int. J. Pharm., 269(2), 457-467.
10. Stuart, D., Löbenberg, R., Ku, T., Azarmi, S., Ely, L., Roa, W., & Prenner, E. J. (2006). Biophysical investigation of nanoparticle interactions with lung surfactant model systems. J. Biomed. Nanotech., 2(3-4), 245-252.
11. Tsapis, N., Bennett, D., Jackson, B., Weitz, D. A., & Edwards, D. A. (2002). Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc. Nat. Acad. Sci. USA, 99, 12001-12005.
12. Wang, Z., Grgic, B., & Finlay, W. H. (2006). A dry powder inhaler with reduced mouth-throat deposition. J. Aerosol. Med., 19, 168-174.